Last €0.27 EUR
Change Today +0.024 / 9.88%
Volume 0.0
RBM On Other Exchanges
As of 10:29 AM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

bg medicine inc (RBM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/25/14 - €1.69
52 Week Low
12/16/14 - €0.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BG MEDICINE INC (RBM)

bg medicine inc (RBM) Related Businessweek News

No Related Businessweek News Found

bg medicine inc (RBM) Details

BG Medicine, Inc., a diagnostics company, develops and commercializes novel cardiovascular diagnostic tests to address unmet medical needs in the United States. The company offers BGM Galectin-3 test, a novel assay for measuring galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of patients diagnosed with heart failure; and CardioSCORE test, which is designed to identify individuals at high risk for cardiovascular events, such as heart attack and stroke. It has license, development, and commercialization agreements with Abbott Laboratories, Alere Inc., bioMérieux SA, and Siemens Healthcare Diagnostics Inc. for the development of galectin-3 test on their automated instrument platforms; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

23 Employees
Last Reported Date: 03/27/14
Founded in 2000

bg medicine inc (RBM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $258.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $275.0K
Compensation as of Fiscal Year 2013.

bg medicine inc (RBM) Key Developments

BG Medicine Receives Non-Compliance Notice From NASDAQ

On November 20, 2014, BG Medicine, Inc. received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC (NASDAQ) indicating that the Company did not meet the minimum $2.5 million in stockholders’ equity, required by NASDAQ Listing Rule 5550(b)(1), which is one of the alternative tests for continued listing on The NASDAQ Capital Market. In the Company’s Form 10-Q filed on August 14, 2014, the Company reported stockholders’ equity of $1,696,000 for the period ended September 30, 2014. In addition, the notice indicates that the Company does not meet the other alternative tests of market value of listed securities or net income from continuing operations and therefore, no longer complies with the continued listing rule. The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on The NASDAQ Capital Market. The notice further provides that the Company has 45 calendar days, or until January 4, 2015, to submit a plan to regain compliance with the continued listing rule. If NASDAQ accepts the Company’s plan to regain compliance, the Company may be granted an extension of up to 180 calendar days from the notice, or until May 19, 2015, to evidence compliance with NASDAQ’s continued listing rule. The Company is currently considering options to resolve this listing deficiency and the deficiency disclosed on Form 8-K filed September 11, 2014 (described below) and to regain compliance. However, there can be no assurance that the Company will be able to regain compliance with The NASDAQ Capital Market listing requirements.

BG Medicine, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year 2014

BG Medicine, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue was $0.695 million against $1.03 million a year ago. The decrease in total revenues reflected a $312,000 decrease in product revenues and a $23,000 decrease in service revenues from the prior year quarter. The decrease in product revenues resulted from a $141,000 decline in orders from largest clinical laboratory customer and a $196,000 decline in purchases related relating to independent research studies, that were partially offset by increased revenues of $25,000 from product related royalties and product sales to other clinical laboratory customers. Loss from operations was $2.233 million against $3.363 million a year ago. Net loss was $2.4 million against $3.66 million a year ago. Basic and diluted net loss per share was $0.07 against $0.13 a year ago. Cash flow used in operating activities decreased by $1.9 million, a 48% decrease, to $2.1 million in the third quarter of 2014 compared to an operating cash burn of $4.0 million in the third quarter of 2013. For the nine months, the company reported total revenue was $2.23 million against $2.92 million a year ago. Loss from operations was $6.15 million against $12.71 million a year ago. Net loss was $6.74 million against $13.91 million a year ago. Basic and diluted net loss per share was $0.21 against $0.52 a year ago. Net cash flows used in operating activities was $7.097 million against $12.820 million a year ago. For the full year 2014, the company expects full year 2014 revenues to be between $2.8 and $3.0 million, in light of the decrease in year-to-date revenues from large clinical laboratory customer and the lack of predictability of sales relating to independent research studies and notwithstanding the modest revenue growth that is achieving from the sales of products to the majority of clinical laboratory customers. For the full year 2014, the company continues to expect to decrease operating cash burn as compared to 2013.

BG Medicine, Inc. to Report Q3, 2014 Results on Nov 13, 2014

BG Medicine, Inc. announced that they will report Q3, 2014 results at 8:30 AM, US Eastern Standard Time on Nov 13, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RBM:GR €0.27 EUR +0.024

RBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $38.04 USD -0.36
Bio-Reference Laboratories Inc $30.80 USD +0.89
BioMerieux €86.21 EUR +0.71
Laboratory Corp of America Holdings $106.98 USD +1.18
Quest Diagnostics Inc $66.91 USD +0.57
View Industry Companies

Industry Analysis


Industry Average

Valuation RBM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.4x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BG MEDICINE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at